Helix Acquisition CORP Ii Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Marc Cobo, Principal Accounting Officer at BridgeBio Oncology Therapeutics, Inc., reported a transaction involving the withholding of shares for tax obligations.
BridgeBio Oncology Therapeutics COO & Principal Financial Officer Idan Elmelech sold 343 shares of common stock for $7.80 per share to cover tax obligations.
BridgeBio Oncology Therapeutics reports a Form 4 filing detailing the acquisition of common stock by Chief Medical & Development Officer Ben Yong, with shares withheld for tax obligations.
BridgeBio Oncology Therapeutics reports a transaction involving President and CEO Pedro Beltran, who had shares withheld for tax obligations.
Bihua Chen reports changes in beneficial ownership of BridgeBio Oncology Therapeutics, Inc. (BBOT) common stock, detailing distributions and indirect holdings.
Praveen Tipirneni, a Director at BridgeBio Oncology Therapeutics, Inc., has reported the acquisition of stock options.
Frank McCormick, a Director at BridgeBio Oncology Therapeutics, Inc., has been granted stock options with a potential exercise price of $7.73.
BridgeBio Oncology Therapeutics, Inc. Director Peter Lebowitz acquired stock options, as disclosed in a Form 4 filing.
Raymond J. Kelleher, a Director at BridgeBio Oncology Therapeutics, Inc., acquired stock options for 31,675 shares.
Bihua Chen, a Director and 10% owner of BridgeBio Oncology Therapeutics, Inc., was granted stock options for 31,675 shares.
BridgeBio Oncology Therapeutics, Inc. director Jake Bauer was granted stock options with an exercise price of $7.73, exercisable starting June 16, 2026.
BridgeBio Oncology Therapeutics, Inc. director Neil Kumar was granted stock options with an exercise price of $7.73, exercisable starting June 16, 2026.
Idan Elmelech, COO & Principal Financial Officer of BridgeBio Oncology Therapeutics, Inc., exercised stock options for 758,222 shares.
Pedro Beltran, President and CEO of BridgeBio Oncology Therapeutics, Inc., has filed a Form 4 detailing changes in beneficial ownership, specifically related to stock options.
Chief Medical & Development Officer Ben Yong reported the withholding of 1,047 shares to cover tax obligations upon RSU vesting.
CEO Pedro Beltran disposed of 1,047 shares of BridgeBio Oncology Therapeutics to satisfy tax obligations related to RSU vesting.
Former officer Uneek Mehra reported the withholding of 524 shares of BridgeBio Oncology Therapeutics common stock to satisfy tax obligations.
BridgeBio Oncology Therapeutics Director Peter F. Lebowitz acquired 63,350 stock options with an exercise price of $8.72, vesting monthly over 36 months.
BridgeBio Oncology Therapeutics' CFO, Uneek Mehra, received grants of 23,330 restricted stock units and options for 105,000 shares.
BridgeBio Oncology Therapeutics' Chief Scientific Officer, Pedro Beltran, received grants of 46,670 restricted stock units and options to purchase 210,000 shares.
BridgeBio Oncology Therapeutics, Inc. granted restricted stock units and stock options to its Chief Medical and Development Officer, Ben Yong, as part of his compensation.
BridgeBio Oncology Therapeutics CEO Eli Wallace received a grant of 1,114,400 stock options with an exercise price of $12.52, vesting through October 2029.
BridgeBio Oncology Therapeutics CEO Eli M. Wallace reported the rescission of 1,114,400 stock options, with 500,000 options remaining outstanding.
BridgeBio Pharma LLC acquired 784,720 shares of BridgeBio Oncology Therapeutics common stock in exchange for services.
BridgeBio Oncology Therapeutics CEO Eli Wallace received a grant of 1,614,400 stock options with an exercise price of $12.44, vesting over four years.
BridgeBio Oncology Therapeutics director Praveen Tipirneni was granted 52,269 stock options with a vesting schedule tied to continuous service and an S-8 filing.
BridgeBio Oncology Therapeutics director Frank McCormick received 91,076 stock options with a $9.59 exercise price, vesting over four years.
BridgeBio Oncology Therapeutics Director Jake Bauer was granted 138,193 stock options with an exercise price of $9.59, vesting over four years.
BridgeBio Oncology Therapeutics' Chief Scientific Officer, Pedro Beltran, was granted options to purchase 357,177 shares of common stock at an exercise price of $9.59.
BridgeBio Oncology Therapeutics' Chief Medical and Development Officer, Ben Yong, was granted 357,177 stock options with an exercise price of $9.59.